top of page


Our science is making news.
Stay in touch.

Follow us on LinkedIn.

Join our mailing list

Thanks for subscribing!

Authors: Katrin Rupalla, Michel Janicot, Alexej Schmidt, Iris Helfrich, Bernhard B. Singer

Full Title: Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy, and significantly increases tumor-associated B-cell population in syngeneic liver Hepa1-6 tumor microenvironment

This poster was presented at the SITC 2022.

SITC poster_final
Download PDF • 2.43MB

RIEHEN, SWITZERLAND, October 18, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM (carcinoembryonic antigen-related cell adhesion molecules) antibodies as anti-cancer treatments, has been selected by BIO-Europe 2022 to present at the Start-up Spotlight session on October 25, 2022 in Leipzig, Germany. The Startup Spotlight is a pitch competition featuring the most innovative startup biotech companies. This live pitch competition gives a group of hand-selected startups the opportunity to pitch in front of the BIO-Europe audience. Selected companies will present a four-minute pitch and participate in a live feedback session with a jury of leading investors, pharma dealmakers, and biotech business key opinion leaders who will evaluate the pitches and select the winner onsite.

“We’re looking forward to sharing our findings with this very innovative group,” said Dr. Katrin Rupalla, CEO, Ymmunobio AG. Dr. Rupalla will present Ymmunobio’s findings on the anti-tumor efficacy in anti-PD-1 sensitive and anti-PD-1 resistant in vivo Hepa1-6 models. The anti-tumor activity is correlated with changes in the immune compartment of the tumor microenvironment. BIO-Europe 2022 takes place October 24-26 and attracts a wide range of business leaders, such as: senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors, and other industry experts. The competition will begin in Multi-purpose Room 3 at 3:30 pm at the Leipzig Messe in Leipzig, Germany, October 25, 2022.

Ymmunobio to Present Pre-Clinical Data on the Anti-Cancer Activity of Lead Asset YB-200 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer.

Read more here:

bottom of page